Royalty Report: Drugs, cardiac, Pharmaceuticals – Collection: 4994

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • cardiac
  • Pharmaceuticals
  • Therapeutic
  • Biotechnology
  • Cancer
  • Delivery
  • Congestive Heart Failure

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4994

License Grant
The Company has an exclusively license for patents and a patent application for the composition and production of the stable prostacyclin analog now known as UT-15 for the treatment of pulmonary hypertension and congestive heart failure and for late-stage peripheral vascular disease.

IPSCIO Record ID: 29073

License Grant
The Licensee entered into an agreement with the University which granted us an exclusive worldwide license, with the right to sublicense, to certain technology covering development, manufacture, use and sale of gene therapy products based on FGF-4 for the treatment of coronary artery disease, peripheral vascular disease and congestive heart failure. FGF-4 shall mean Fibroblast Growth Factor 4, the amino acid sequence.
Field of Use
Field shall mean gene therapy for coronary artery disease, congestive heart failure, and peripheral vascular disease.

IPSCIO Record ID: 27221

License Grant
In 1998, the Company entered into a cooperative drug discovery agreement to identify and develop an antisense therapy as a potential treatment for pulmonary hypertension.
License Property
Pulmonary hypertension (PH or PHT) is an increase in blood pressure in the pulmonary artery, pulmonary vein, or pulmonary capillaries, together known as the lung vasculature, leading to shortness of breath, dizziness, fainting, and other symptoms, all of which are exacerbated by exertion. Pulmonary hypertension can be a severe disease with a markedly decreased exercise tolerance and heart failure.
Field of Use
The Field of Use apply to the medical industry.

IPSCIO Record ID: 5058

License Grant
The Licensee entered into an agreement granting it the exclusive right to Licensor’s know-how for the design, development, production, and use of a technology known as pegylation drug formulation and delivery to develop and produce sustained release prostacyclin molecules for the possible treatment of pulmonary hypertension, peripheral vascular disease, stroke, heart disease, cancer, and related diseases worldwide.

IPSCIO Record ID: 230780

License Grant
The Swiss Licensor hereby grants to the Canadian Licensee a perpetual, world-wide exclusive license, with the right to grant sub-licenses, at the royalty rates set out to the Purchased Assets and the Arising Patents and the know how related thereto for Cardiovascular Indications, which Licensee shall exploit at its own risk and without any possible recourse of whatever nature against Licensor or any of its Affiliates.
License Property
For the purposes of this Agreement, 'Cardiovascular Indications' means heart failure, coronary artery disease, arterial hypertension or systemic hypertension, arrhythmias (including atrial, nodal, and ventricular), hypertension, peripheral vascular disorders, shock, endocarditis, pericardial disease, cardiac tumors, vaivular heart disease and angina only. For the avoidance of doubt, Cardiovascular Indications do not include cerebrovascular diseases, pulmonary hypertension and Chronic Obstructive Pulmonary Disease. Within a reasonable time after the invention or creation of any Arising Patents and the know how related thereto, Licensor will notify and provide reasonable particulars of same to Licensee.

'Existing Patents' means the RSD930 and RSD1236 Patent Families (ApplicationNumbers US 09/328,540; PCT/CA99/00535; US 09/328,541; PCT/CA99/00534; PCT/CA00/01506; PCT/CA00/01507; PCT/CA00/01508; PCT/CA98/00842 and Thailand Patent Appl.# 045858; Taiwan Patent Appl.# 87114395; The Philippines Patent Appl. # 98/2246; and Malaysia Patent Appl. # Pl 9804017 and all patentm applications claiming priority therefrom or sharing at least one common priority therewith).

Field of Use
The rights granted apply to the drug industry in the respiratory field for cardiovascular indications.

IPSCIO Record ID: 29203

License Grant
The Canadian University Licensor granted to the Licensee an exclusive worldwide royalty-bearing License under its Patent Rights and Intellectual Property Rights to research and develop, make, have made, use, promote, sell, market and distribute Licensed Products during the term of this Agreement. These rights include the right to apply for and/or acquire world-wide Patent Rights on behalf of University and to grant sublicenses.
License Property
The licensed products are pyridoxine, pyridoxal-5-phosphate, pyridoxal, pyridoxamine, 4-pyridoxic acid, 3-acylated analogues of pyridoxal and 3-acylated analogues of pyridoxal-4,5-aminal for the therapeutic use of pyridoxine, pyridoxal-5- phosphate, pyridoxal and pyridoxamine for hypertrophy, congestive heart failure, ischemic reperfusion injury, arrhythmia, hypertension and contractile dysfunction subsequent to myocardial infarction.
Field of Use
Licensed Field means a) the therapeutic use of pyridoxine, pyridoxal-5- phosphate, pyridoxal and pyridoxamine for hypertrophy, congestive heart failure, ischemic reperfusion injury, arrhythmia, hypertension and contractile dysfunction subsequent to myocardial infarction; b) treatment of hypertension in patients receiving at least one NSAIDs with pyridoxine, pyridoxal-5-phosphate, pyridoxal, pyridoxamine and 4-pyridoxic acid; c) the compound and use of 3-acylated analogues of pyridoxal and 3-acylated analogues of pyridoxal-4,5-aminal; claimed in the Patent Rights.

IPSCIO Record ID: 25991

License Grant
As part of a License Agreement transaction, the Licensee acquired rights and corresponding obligations to the University.  Upon assumption, this agreement provides the Licensee with exclusive rights in the cardiac fields to develop and commercialize technology covered by the issued patent and patent applications that have been filed in the United States and in foreign countries.
License Property
The Technology covers development, manufacture, use and sale of gene therapy products for the treatment of coronary artery disease, peripheral vascular disease and congestive heart failure.
Field of Use
The Licensee develops products based on gene therapy, manufacturing process and technology platforms for cardiovascular disease, wound healing and tissue engineering.

IPSCIO Record ID: 7466

License Grant
The Licensor, government public health organization, hereby grants and Licensee accepts, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
Development and commercialization of this technology will provide treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion and inflammation of the cardiovascular system. Development and commercialization of this technology will also provide treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.
Field of Use
Fields of Use of the Licensed Property is for prevention, treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion, inflammation of the cardiovascular system and the treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.

IPSCIO Record ID: 26103

License Grant
The asset purchased with the company is a novel gene therapy through preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF).
License Property
Licensor is an early-stage biotechnology company,effectively a single-product business, fully focusing on the further development of gene therapy approaches for cardiac disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.